Context Therapeutics Ownership | Who Owns Context Therapeutics?


OverviewForecastFinancialsChart

Context Therapeutics Ownership Summary


Context Therapeutics is owned by 4.37% institutional investors, 1.18% insiders, and 94.45% retail investors. Bioimpact capital is the largest institutional shareholder, holding 11.62% of CNTX shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.48% of its assets in Context Therapeutics shares.

CNTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockContext Therapeutics4.37%1.18%94.45%
SectorHealthcare Stocks 35.34%11.88%52.77%
IndustryBiotech Stocks 35.37%11.83%52.80%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bioimpact capital10.68M11.62%$27.98M
Nextech invest7.42M9.22%$7.79M
Deep track capital, lp7.42M8.08%$19.44M
Nextech invest7.42M8.08%$19.44M
Soleus capital management6.96M7.58%$18.24M
Octagon capital advisors lp5.25M5.71%$13.76M
Blue owl capital lp5.09M5.54%$13.33M
Avidity partners management lp5.00M5.44%$11.80M
Blackrock851.70K5.33%$1.71M
Franklin resources3.80M4.14%$9.96M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Blue owl capital lp5.09M3.58%$13.33M
Avidity partners management lp5.00M2.67%$11.80M
Bioimpact capital10.68M2.16%$27.98M
Octagon capital advisors lp5.25M1.52%$13.76M
Nextech invest7.42M1.37%$19.44M
Great point partners2.24M1.35%$5.86M
Nextech invest7.42M1.26%$7.79M
Soleus capital management6.96M0.74%$18.24M
Sio capital management917.92K0.34%$2.40M
Deep track capital, lp7.42M0.32%$19.44M

Top Buyers

HolderShares% AssetsChange
Soleus capital management6.96M0.74%6.96M
Octagon capital advisors lp5.25M1.52%5.25M
Tcg crossover management2.68M0.20%2.68M
Susquehanna group, llp1.09M0.00%1.09M
Adage capital partners gp1.00M0.00%1.00M

Top Sellers

HolderShares% AssetsChange
Great point partners2.24M1.35%-2.45M
Blackstone---2.44M
Blue owl capital lp5.09M3.58%-2.34M
Driehaus capital management---2.26M
Alyeska investment group---1.66M

New Positions

HolderShares% AssetsChangeValue
Soleus capital management6.96M0.74%6.96M$18.24M
Octagon capital advisors lp5.25M1.52%5.25M$13.76M
Tcg crossover management2.68M0.20%2.68M$7.03M
Adage capital partners gp1.00M0.00%1.00M$2.62M
Blackrock851.70K-851.70K$1.71M

Sold Out

HolderChange
Wells fargo & company/mn-116.00
Barclays-167.00
Advisornet financial-200.00
Federation des caisses desjardins du quebec-400.00
Newbridge financial services group-2.00K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202612-71.43%4,160,373-93.62%40.09%8-52.94%1-87.50%
Dec 31, 202510-72.97%16,071,417-76.70%160.32%3-75.00%3-57.14%
Sep 30, 20255-87.18%3,733,804-94.56%30.08%3-76.92%--100.00%
Jun 30, 202539-9.30%68,619,080-3.91%721.28%1220.00%9-35.71%
Mar 31, 20259-82.69%31,512,715-56.71%330.40%--100.00%1-91.67%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF3.12M3.48%-6.75K
Vanguard Total Stock Mkt Idx Inv2.82M3.06%-
Franklin Biotechnology Discv A(acc)USD2.40M2.62%-
Franklin Biotechnology Discovery A1.40M1.52%-80.37K
Vanguard Institutional Extnd Mkt Idx Tr520.90K0.57%-
Calamos Market Neutral Income A277.81K0.30%-
Fidelity Extended Market Index260.31K0.28%12.57K
Belfund SICAV Belinvest Equity A USD Acc260.00K0.28%-
BlackRock Extended Equity Market K104.84K0.14%-45.00
Blackrock Extended Mkt Fund CF120.30K0.13%-

Recent Insider Transactions


DateNameRoleActivityValue
Jun 09, 2025Lehr Martin A. Chief Executive OfficerBuy$70.08K
Jun 06, 2025Levit Alex C. Chief Legal Officer, Corp. SecBuy$11.52K
Jun 06, 2025Minai-Azary Jennifer Lynn Chief Financial OfficerBuy$25.49K
Feb 21, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K
Feb 13, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K

Insider Transactions Trends


DateBuySell
2025 Q23-
2025 Q1--
2024 Q3--
2024 Q2--
2024 Q1--

CNTX Ownership FAQ


Who Owns Context Therapeutics?

Context Therapeutics shareholders are primarily institutional investors at 4.37%, followed by 1.18% insiders and 94.45% retail investors. The average institutional ownership in Context Therapeutics's industry, Biotech Stocks , is 35.37%, which Context Therapeutics falls below.

Who owns the most shares of Context Therapeutics?

Context Therapeutics’s largest shareholders are Bioimpact capital (10.68M shares, 11.62%), Nextech invest (7.42M shares, 9.22%), and Deep track capital, lp (7.42M shares, 8.08%). Together, they hold 28.92% of Context Therapeutics’s total shares outstanding.

Does Blackrock own Context Therapeutics?

Yes, BlackRock owns 5.33% of Context Therapeutics, totaling 851.7K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.71M$. In the last quarter, BlackRock increased its holdings by 851.7K shares, a 100.00% change.

Who is Context Therapeutics’s biggest shareholder by percentage of total assets invested?

Blue owl capital lp is Context Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.58% of its assets in 5.09M Context Therapeutics shares, valued at 13.33M$.

Who is the top mutual fund holder of Context Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Context Therapeutics shares, with 3.48% of its total shares outstanding invested in 3.12M Context Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools